BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27581354)

  • 1. Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.
    Légaré S; Basik M
    Mol Endocrinol; 2016 Sep; 30(9):965-76. PubMed ID: 27581354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
    Jiang S; Meyer R; Kang K; Osborne CK; Wong J; Oesterreich S
    Mol Endocrinol; 2006 Feb; 20(2):311-20. PubMed ID: 16195251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
    Keeton EK; Brown M
    Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
    Sharma D; Saxena NK; Davidson NE; Vertino PM
    Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
    Cutrupi S; Reineri S; Panetto A; Grosso E; Caizzi L; Ricci L; Friard O; Agati S; Scatolini M; Chiorino G; Lykkesfeldt AE; De Bortoli M
    Oncogene; 2012 Oct; 31(40):4353-61. PubMed ID: 22249258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells.
    Hong W; Chen L; Li J; Yao Z
    Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.
    Lu R; Hu X; Zhou J; Sun J; Zhu AZ; Xu X; Zheng H; Gao X; Wang X; Jin H; Zhu P; Guo L
    Nat Commun; 2016 Jul; 7():12044. PubMed ID: 27375289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa.
    Ma H; Li L; Dou G; Wang C; Li J; He H; Wu M; Qi H
    Oncotarget; 2017 Apr; 8(17):29328-29345. PubMed ID: 28415616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
    Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
    Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor corepressors -- a role in human breast cancer?
    Dobrzycka KM; Townson SM; Jiang S; Oesterreich S
    Endocr Relat Cancer; 2003 Dec; 10(4):517-36. PubMed ID: 14713265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases.
    Lopez-Garcia J; Periyasamy M; Thomas RS; Christian M; Leao M; Jat P; Kindle KB; Heery DM; Parker MG; Buluwela L; Kamalati T; Ali S
    Nucleic Acids Res; 2006; 34(21):6126-36. PubMed ID: 17085477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid Receptor:MegaTrans Switching Mediates the Repression of an ERα-Regulated Transcriptional Program.
    Yang F; Ma Q; Liu Z; Li W; Tan Y; Jin C; Ma W; Hu Y; Shen J; Ohgi KA; Telese F; Liu W; Rosenfeld MG
    Mol Cell; 2017 May; 66(3):321-331.e6. PubMed ID: 28475868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
    Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
    Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
    Graham JD; Bain DL; Richer JK; Jackson TA; Tung L; Horwitz KB
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):255-9. PubMed ID: 11162933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.